Advertisement
Oxcia appoints Eva Sjökvist Saers as Chairman of the Board

“It is a great advantage for me to have her by my side in the continued development of Oxcia and the technology platform, O2-DDR,” emphasizes Oxcia’s CEO, Ulrika Warpman Berglund.
The former Chairman of the Board since 2021, Jan Zetterberg, is a co-founder of Oxcia and was its CEO from 2014 to 2020.
Eva Sjökvist Saers
Eva Sjökvist Saers has worked on Oxcia’s Board of Directors since 2020 and has a long industrial life science background at senior level, including within Astra/AstraZeneca and as CEO of the pharmaceutical company APL. Eva Sjökvist Saers currently works on the boards of a number of companies, as chairman of Coegin Pharma AB and Dicot Pharma AB and as a board member of Alligator Bioscience AB, Apoex AB, Bluefish Pharmaceuticals AB and NextCell Pharma AB, as well as chairman of Swelife – a strategic innovation program. Eva is well versed in Oxcia’s business, has a deep understanding of the industry and a broad network.
“It is with great enthusiasm that I take over the baton from Jan,” says Eva Sjökvist Saers. I look forward to our continued joint work to significantly extend and improve the lives of patients affected by serious diseases such as cancer and inflammatory diseases.”
Updated: February 16, 2025, 05:43 pm
Published: February 10, 2025